Latest Sirolimus Stories
EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of AfinitorÂ® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET).
PARIS, May 25, 2010 /PRNewswire/ -- - NEVO(TM), Incorporating RES TECHNOLOGY(TM), Continues to Support Excellent Safety and Efficacy Outcomes vs.
SAN DIEGO, May 7 /PRNewswire/ -- Patients treated with the ZilverÂ® PTX(TM) Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the ZilverÂ® PTX(TM) Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.
If research results continue to be repeated and are turned into clinical trials, a drug already approved for some uses could be marshaled â€” sooner than we expect â€” to prevent Alzheimer's disease in humans and improve health to the end of life.
Sirolimus-based immunosuppression and radiofrequency ablation are promising treatments for HCC.
WATERLOO, Belgium, March 17, 2010 /PRNewswire/ -- - SORT OUT III Data Presented at American College of Cardiology Meeting in Atlanta and Published in the Lancet Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical differences.
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease.
JAMAICA PLAIN, Mass., Feb. 4 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).
Research performed at UC Santa Barbara points to the drug rapamycin as a potential treatment for kidney disease.